EyePoint, Inc. will participate in multiple upcoming conferences to discuss advancements in retinal disease therapeutics.
Quiver AI Summary
EyePoint, Inc., a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, announced its participation in upcoming conferences, including the Citi 2026 Biopharma Back to School Conference and the Cantor Global Healthcare Conference. The company will also present research at The Retina Society's 59th Annual Scientific Meeting, showcasing its investigational product, DURAVYU™, a sustained delivery treatment for retinal diseases. Presentations will cover various aspects of their lead product candidate, EYP-1901, including its safety and efficacy in treating neovascular age-related macular degeneration. EyePoint, committed to improving patients' lives with innovative therapies, is currently evaluating DURAVYU™ in Phase 3 trials.
Potential Positives
- EyePoint's participation in multiple prominent healthcare conferences enhances its visibility and engagement with investors and key stakeholders in the biopharmaceutical industry.
- The upcoming scientific presentations on the company's lead product candidate, DURAVYU™, aim to showcase robust clinical data related to its efficacy and safety, potentially improving investor confidence.
- EyePoint’s commitment to developing innovative therapeutics for serious retinal diseases positions it as a leader in a specialized market with significant unmet medical needs.
Potential Negatives
- DURAVYU™ is still an investigational product and has not yet received FDA approval, indicating uncertainty in its market readiness and potential revenue generation.
- There is a lack of definitive results or data regarding the efficacy and safety of the lead product candidate, which could raise investor concerns about the company's future prospects.
- The company has a history of four approved drugs over three decades, which may highlight a slower pace of innovation compared to industry peers.
FAQ
What conferences will EyePoint participate in September 2026?
EyePoint will participate in the Citi Biopharma Conference, Cantor Global Healthcare Conference, and Morgan Stanley Healthcare Conference.
Who will present at The Retina Society meeting?
Presenters include Ehsan Rahimy, M.D., Carl D. Regillo, M.D., and Charles C. Wykoff, M.D., among others.
What is the focus of EyePoint's presentations at the scientific meeting?
The focus includes the EYP-1901 insert's effectiveness in treating retinal diseases like neovascular AMD.
How can I access EyePoint conference webcasts?
Webcasts of the fireside chats can be accessed via the Investors section on EyePoint's website.
What is EyePoint's lead product candidate?
EyePoint's lead product candidate is DURAVYU™, an investigational treatment for retinal diseases combining vorolanib with Durasert E™ technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- RAMIRO RIBEIRO (Chief Medical Officer) has made 0 purchases and 2 sales selling 4,875 shares for an estimated $80,126.
- KAREN L. ZADEREJ purchased 10,600 shares for an estimated $52,258
- JAY S. DUKER (President and CEO) purchased 1,500 shares for an estimated $19,723
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EYPT Hedge Fund Activity
We have seen 89 institutional investors add shares of $EYPT stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC removed 3,572,335 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $46,047,398
- CITADEL ADVISORS LLC added 1,905,875 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,566,728
- COMMODORE CAPITAL LP added 1,775,000 shares (+62.8%) to their portfolio in Q2 2026, for an estimated $25,382,500
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,527,792 shares (+46.3%) to their portfolio in Q2 2026, for an estimated $21,847,425
- CORMORANT ASSET MANAGEMENT, LP removed 1,265,000 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $18,089,500
- SPRUCE STREET CAPITAL LP removed 981,543 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,652,089
- MORGAN STANLEY removed 759,379 shares (-69.3%) from their portfolio in Q2 2026, for an estimated $10,859,119
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$EYPT Price Targets
Multiple analysts have issued price targets for $EYPT recently. We have seen 5 analysts offer price targets for $EYPT in the last 6 months, with a median target of $47.0.
Here are some recent targets:
- Steve Seedhouse from Cantor Fitzgerald set a target price of $47.0 on 07/08/2026
- Andreas Argyrides from Chardan Capital set a target price of $65.0 on 07/01/2026
- Yatin Suneja from Guggenheim set a target price of $68.0 on 06/24/2026
- Lisa Walter from RBC Capital set a target price of $37.0 on 05/07/2026
- Yigal Nochomovitz from Citigroup set a target price of $35.0 on 03/09/2026
Full Release
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:
-
Citi 2026 Biopharma Back to School Conference
Forum: Fireside Chat
Date: September 9, 2026
Time: 8:00 am ET
-
Cantor Global Healthcare Conference 2026
Forum: Fireside Chat
Date: September 10, 2026
Time: 10:20 am ET
-
Morgan Stanley Global Healthcare Conference
Forum: Fireside Chat
Date: September 15, 2026
Time: 7:00 am ET
A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors section of the Company website at
www.eyepoint.bio
.
Scientific Meeting
EyePoint will be participating at The Retina Society 59th Annual Scientific Meeting from September 23-26, 2026, in Los Angeles, CA.
-
Presentation:
Bioerodible EYP-1901 (Vorolanib Intravitreal Insert) for Sustained Release of a Tyrosine Kinase Inhibitor for Retinal Exudative Disease: Mechanism of Action and Pharmacokinetic Characteristics
Presenter: Ehsan Rahimy, M.D.
Date & Time (Session): September 24, 2026 | 11:15 AM PT (AMD I)
-
Presentation:
LUGANO Phase 3 Trial of Bioerodible EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (nAMD): First-Time Vision and Anatomic Outcomes
Presenter: Carl D. Regillo, M.D., FACS, FASRS
Date & Time (Session): September 24, 2026 | 11:18 AM PT (AMD I)
-
Presentation:
LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (nAMD): First-Time Safety and Treatment Burden Outcomes
Presenter: Charles C. Wykoff, M.D., Ph.D.
Date & Time (Session): September 24, 2026 | 11:23 AM PT (AMD I)
-
Presentation:
Association Between Central Subfield Thickness (CST) Fluctuation and Visual Acuity (VA) Outcomes in Patients with Neovascular Age-Related Macular Degeneration (nAMD): An IRIS
®
Registry Analysis
Presenter: Durga S. Borkar, MD, MMCi
Date & Time (Session): September 25, 2026 | 3:45 PM PT (AMD III)
Presentations from The Retina Society will be available in the Scientific Publications section of the Company website at www.eyepoint.bio .
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Robin Garner
EyePoint, Inc.
[email protected]
Media:
Helen O’Gorman
FTI Consulting
[email protected]
